Brief report: Two secondary leukemias among 15 children given oral etoposide

Medical and Pediatric Oncology

Volumn 37, Issue 2, 2001, Pages 148-149

  Schiavetti, Amalia ^a   Varrasso, Giulia ^a   Maurizi, Palma ^a   Castello, Manuel A ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Neuroblastoma; Oral etoposide; Secondary leukemia

Indexed keywords

ETOPOSIDE;

ACUTE LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; HISTIOCYTOSIS X; HUMAN; METASTASIS; NEUROBLASTOMA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; ACUTE MONOCYTIC LEUKEMIA; CASE REPORT; CHEMICALLY INDUCED DISORDER; CHILD; PROMYELOCYTIC LEUKEMIA; SECOND CANCER;

CHILD; ETOPOSIDE; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASMS, SECOND PRIMARY; NEUROBLASTOMA;

EID: 0034899185     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.1187     Document Type: Article

References (9)

1. Oral etoposide for refractory and relapsed neuroblastoma
2. Efficacy of palliative oral etoposide (E) in metastatic neuroblastoma (NB) relapsing after high-dose chemotherapy (HDCT)
3. Ten-day schedule oral etoposide therapy in advanced childhood malignancies
4. Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia
5. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins
6. High rate of secondary haematological malignancy (SHM) after continuous treatment by VP-16 (CVP) for a solid tumor in children: A single institution study
7. Etoposide-related acute promyelocytic leukemia
8. Secondary acute promyelocytic leukemia after treatment with etoposide for Langerhans cell histiocytosis. Letter to the Editor
9. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors